When a sponsor’s biologic program expanded from a domestic Phase 1 design into a multi-region trial spanning New Zealand, EMEA, and APAC, the bioanalytical challenge centered on keeping a fragile, time-sensitive sample chain intact across nine additional clinical sites, two outsourced processing labs, and a central analytical lab, all…